Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Eledon Pharmaceuticals (ELDN) EPS (Basic) (2016 - 2026)

Eledon Pharmaceuticals filings provide 5 years of EPS (Basic) readings, the most recent being -$0.05 for Q4 2017.

  • On a quarterly basis, EPS (Basic) rose 70.59% to -$0.05 in Q4 2017 year-over-year; TTM through Dec 2017 was -$2.39, a 67.17% increase, with the full-year FY2024 number at -$36.61, down 674.0% from a year prior.
  • EPS (Basic) hit -$0.05 in Q4 2017 for Eledon Pharmaceuticals, up from -$0.43 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of -$0.05 in Q4 2017 to a low of -$11.68 in Q2 2014.
  • Median EPS (Basic) over the past 5 years was -$0.59 (2015), compared with a mean of -$3.01.
  • Biggest five-year swings in EPS (Basic): surged 97.51% in 2014 and later crashed 720.75% in 2016.
  • Eledon Pharmaceuticals' EPS (Basic) stood at -$11.23 in 2013, then surged by 97.51% to -$0.28 in 2014, then plummeted by 75.0% to -$0.49 in 2015, then skyrocketed by 65.31% to -$0.17 in 2016, then skyrocketed by 70.59% to -$0.05 in 2017.
  • The last three reported values for EPS (Basic) were -$0.05 (Q4 2017), -$0.43 (Q3 2017), and -$1.32 (Q2 2017) per Business Quant data.